Logo
x

Search

Subscribe Now

Akebia

Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD

Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD

  • May 26, 2023
Akebia Receives the MHRA’s Approval of Vafseo for Symptomatic Anemia Associated with Chronic Kidney Disease

Akebia Receives the MHRA’s Approval of Vafseo for Symptomatic Anemia Associated with Chronic Kidney Disease

  • May 23, 2023
Akebia Receives EC’s Marketing Authorisation of Vafseo (vadadustat) for the Treatment of Symptomatic Anaemia

Akebia Receives EC’s Marketing Authorisation of Vafseo (vadadustat) for the Treatment of Symptomatic Anaemia

  • April 26, 2023
Akebia Receives EMA’s CHMP Positive Opinion of Vafseo (vadadustat) for Symptomatic Anaemia Associated with Chronic Kidney Disease

Akebia Receives EMA’s CHMP Positive Opinion of Vafseo (vadadustat) for Symptomatic Anaemia Associated with Chronic Kidney Disease

  • February 24, 2023
Akebia Amended and Restated License Agreement with Vifor Pharma to Launch Vadadustat in the US

Akebia Amended and Restated License Agreement with Vifor Pharma to Launch Vadadustat in the US

  • February 23, 2022
Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

  • February 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.